Skip to Main content Skip to Navigation
Journal articles

Human papillomavirus G-rich regions as potential antiviral drug 1 targets

Abstract : Herein we report for the first time the screening of several ligands in terms of their ability to bind and stabilize G-quadruplexes found in seven human Papillomavirus (HPV) genomes. Using a variety of biophysical assays, HPV G-quadruplexes were shown to possess a high degree of structural polymorphism upon ligand binding which may have an impact on transcription, replication and viral protein production. A sequence found in high-risk HPV16 genotype folds into multiple non-canonical DNA structures; it was converted into a major G-quadruplex conformation upon interaction with a well-characterized highly selective G4-ligand, PhenDC3, which may have animpact on the viral infection. Likewise, HPV57 and 58, which fold into multiple G-quadruplex structures, were found to form single stable complexes in the presence of two other G4-ligands, C8and Pyridostatin, respectively. Additionally, one of the selected compounds, the acridine derivative C8, demonstrated a significant antiviral effect in HPV18-infected organotypic raft cultures. Altogether, these results indicate that targeting HPV G-quadruplexes may be an alternative route for the development of novel antiviral therapies.
Document type :
Journal articles
Complete list of metadata

Cited literature [58 references]  Display  Hide  Download
Contributor : Jean-Louis Mergny Connect in order to contact the contributor
Submitted on : Tuesday, October 6, 2020 - 11:48:27 AM
Last modification on : Friday, August 5, 2022 - 12:40:06 PM
Long-term archiving on: : Thursday, January 7, 2021 - 6:21:48 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document


  • HAL Id : inserm-02958829, version 1



Josué Carvalho, Jéssica Lopes-Nunes, Maria P C Campello, António Paulo, Janice Milici, et al.. Human papillomavirus G-rich regions as potential antiviral drug 1 targets. Nucleic Acid Therapeutics, Mary Ann Liebert, Inc. publishers, In press. ⟨inserm-02958829⟩



Record views